Table: A Long and Winding Road

Some recent biotech drug setbacks


CORIXA: FDA has twice delayed review of this novel BEXXAR antibody for non-Hodgkin's lymphoma, most (CANCER) recently in January, because it needs more time to review the lengthy filing.

AMYLIN: FDA issued a likely-to-approve letter in SMYLIN October, contingent on additional safety (DIABETES) trials, which will take about a year.

GENENTECH FDA asked for more safety and efficacy tests /XOMA: in October, delaying approval filing by at XANELIM least six months.

GENENTECH In July, the FDA rejected the drug, asking for /NOVARTIS: additional safety data. New clinical trials are XOLAIR under way, and the companies expect to (ASTHMA) resubmit the drug at the end of 2002.

CHIRON: The application for this highly sensitive HIV PROCLEIX blood test was accepted by the FDA in March, (BLOOD TEST) 2001, but despite being granted fast-track status, approval wasn't granted until Feb. 28.

    Before it's here, it's on the Bloomberg Terminal.